Amgen 🧪🔬🧬
@Amgen
Amgen harnesses the best of biology and technology to fight the world’s toughest diseases.
🔗 Guidelines:
963 Following 118.5K Followers
At AHA #ScientificSessions26#, Amgen presented data highlighting the cost effectiveness of intensive LDL-C lowering, building on years of established clinical evidence.
Read the press release:
$AMGN
Show more
Why do some people develop heart disease while others don’t?
Amgen research leader and AHA Population Research Prize recipient Pradeep Natarajan shares insights in a new Q&A article.
Show more
B cells are built to protect us. But in autoimmune disease, they can become dysregulated and contribute to disease.
Amgen researchers are exploring whether targeting CD19 could help address that🔬
Show more
📢 Amgen’s real-world study shows that treatment decisions to lower LDL-C impacts heart attack risk in ASCVD patients.
The findings prompt a closer look at how we approach LDL-C lowering in clinical practice.
🔗
$AMGN
Show more
Amgen reports Q3 2026 earnings:
Amgen delivered another strong quarter, reflecting the performance our strategy was designed to achieve.
Safe Harbor:
$AMGN
Show more
Amgen will report Q3 2026 earnings tomorrow.
Details here:
$AMGN
At AHA #ScientificSessions26#, Amgen is adding to its extensive base of cardiovascular evidence, with new research exploring LDL-C management, long-term outcomes and the economic considerations of care.
Explore our abstracts ⬇️
Show more
Every story is personal. Every voice can help bring our mission into focus. Meet people whose experiences with cancer, cardiovascular disease, rare disease and obesity have shaped their lives and perspectives.
At Amgen, serving patients is our mission. We’re honored to be named to @TIME World’s Best Companies 2026 list:
Show more
Amgen will report Q3 2026 financial results on Tuesday, November 3.
Details here:
$AMGN
Innovation has deep roots in Massachusetts, and Amgen is proud to have been part of its life sciences community for 25 years. From our research center in Cambridge, our teams continue to push the boundaries of science to advance medicines for patients around the world.
Learn more about our history in Massachusetts:
Show more
Amgen today announced the appointment of David W. Gibbs, former president and CEO of Yum! Brands, to its Board of Directors. He brings experience leading global consumer brands and building direct customer relationships.
Show more
#NEWS#: At #ESMO26#, Amgen presents late-breaking data for our DLL3-targeting T-cell engager, with findings simultaneously published in @NEJM.
These landmark results add to our growing body of evidence across the #SCLC# treatment journey.
Read more:
$AMGN
Show more
🔬 Research to watch at @myESMO’s #ESMO26#. We're sharing new data across small cell lung cancer (SCLC) and our broader T-cell engager pipeline, including late-breaking research.
Search for abstracts LBA3, 3821P and 3808O:
Show more
📢 Amgen announced positive full Phase 3 results in eosinophilic esophagitis (EoE), a chronic inflammatory disorder of the esophagus that can make swallowing and eating challenging.
🔗 Learn more:
$AMGN
Show more
What would it take to close post-fracture care gaps in postmenopausal osteoporosis?
At #ASBMR2026#, Amgen leaders are weighing in on where action is needed to strengthen care coordination and help reduce the risk of future fractures. Explore their perspectives now.
Show more
🔬Will you be at #ASBMR2026#? Explore our latest real-world data highlighting encouraging new insights on changes in hip bone strength in postmenopausal women:
📊 Plenary Poster Session:
Fri, Oct. 9 | 5:30–7:00 PM
📊 Poster Session I:
Sat, Oct. 10 | 2:00–3:30 PM
Show more
Biosimilars have the potential to save the U.S. healthcare system $180B by the end of 2027, but bringing a biosimilar to patients not an easy journey. In fact, it can take 6-9 years and cost hundreds of millions of dollars.
Follow the journey here to see exactly what it takes:
Show more
What do people living with obesity need for their long-term care? We’re at @EASDNews talking about patient-centered care and research.
See what we’re discussing. ➡️ #EASD2026#
Show more
📢 #SjogrensDisease# News: Amgen announced that a Phase 3 study evaluating its investigational therapy in patients with moderate-to-severe systemic disease activity met its primary endpoint:
$AMGN
Show more
We stand up for every child affected by cancer. 🧡 That’s why #StandUpToCancer# teamed up with @MrBeast and @BeastPhilanthr to create a new SU2C Pediatric Cancer Dream Team focused on finding cures for kids with cancer, fueled by support from @Amgen and @StBaldricks.
This #ChildhoodCancerAwarenessMonth#, help end pediatric cancer by donating at
Show more
